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Background
Progressive liver fibrosis is the main cause of organ fail-
ure in chronic liver diseases of any etiology. Advanced liver 
fibrosis results in cirrhosis that can in turn lead to liver fail-
ure, portal hypertension and hepatocellular carcinoma (1, 
2). Fibrosis develops with different spatial patterns and is a 
consequence of various prevalent mechanisms according to 
the diverse causes of parenchymal damage. Early detection 
of fibrosis would allow for initiation of anti-fibrotic thera-
pies capable of halting and even reversing this process. This 
would in turn prevent progression to hepatic cirrhosis, and 
the morbidity and mortality this condition entails (3). To 
date, liver biopsy remains the gold standard for the evalua-
tion of liver fibrosis. However, its invasiveness, the observa-
tions of significant side effect profile, and susceptibility of 
this technique to sampling error ultimately make it a sub-
optimal technique (4, 5). For these reasons, it is necessary to 
find out new, reliable, and non-invasive diagnostic methods 
for identifying patients with liver fibrosis. Simple biochemi-
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ABSTRACT
   
Background: The aspartate aminotransferases (AST) to platelet ratio index (APRI) may serve 
as a noninvasive marker to assess liver fibrosis.
Objectives: To assess the diagnostic ability of the APRI for prediction of fibrosis in patients 
with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver dis-
ease (NAFLD).
Patients and Methods: This retrospective study included 207 patients with CHB, 108 with CHC, 
and 140 patients with NAFLD. The APRI was calculated as (AST level/upper normal limit for 
AST)/platelet counts (109/L) × 100. The stage of liver fibrosis in patients with chronic viral 
hepatitis was graded using the METAVIR scale. The Kleiner system for grading fibrosis was 
used in patients with NAFLD. 
Results: Bivariate correlation analyses showed that the APRI was significantly associated 
with fibrosis scores in patients with CHC (p = 0.2634, p = 0.0059) and NAFLD (p = 0.2273, 
p = 0.0069), but not in those with CHB (p = 0.1005, p = 0.1495). Receiver operating char-
acteristic (ROC) curves were used for assessing the ability of the APRI as a predictor of the 
absence or presence of liver fibrosis (fibrosis score of 0 vs fibrosis scores of 1-4). In patients 
with CHC, the APRI showed a  sensitivity of 72.7% and a specificity of 62.4% for detection of 
fibrosis (p<0.01). In the NAFLD group, the APRI showed a sensitivity of 60.0% and specificity 
of 73.3% for detection of fibrosis (p<0.01). In patients with CHB, the APRI showed a sensitivity 
of 55.0% and a specificity of 75.4% for fibrosis (p=NS). 
Conclusions: The APRI shows an acceptable accuracy for the assessment of liver fibrosis in 
patients with CHC and NAFLD, but not in those with CHB. 
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In patients with chronic viral hepatitis, fibrosis was grad-
ed according to the METAVIR scale (13), which grades fibro-
sis on a five-point scale as follows: F0, no fibrosis; F1, portal 
fibrosis without septa; F2, portal fibrosis with a few septa; 
F3,  numerous  septa  without  cirrhosis,  and  F4,  cirrhosis. 
The  METAVIR  scale  has  excellent  inter-observer  reliability. 
The Kleiner system was used for grading fibrosis in patients 
with NAFLD (14). According to the Kleiner system, fibrosis is 
staged as follows: Stage 0, no fibrosis; stage 1, perisinusoidal 
or  periportal  fibrosis;  stage  2,  perisinusoidal  and  portal/
periportal fibrosis; stage 3, bridging fibrosis; and stage 4, 
cirrhosis. Bivariate Spearman’s rank correlation coefficients 
(p) were used to assess correlations between the study vari-
ables. Receiver operating characteristic (ROC) curves were 
used to assess the usefulness of the APRI as a predictor of 
the absence or presence of liver fibrosis (fibrosis score of 0 
vs fibrosis scores of 1-4) in each group of patients. All statis-
tical analyses were performed using the MedCalc software 
package version 7.2 for Windows® (MedCalc, Mariakerke, 
Belgium). A p value <0.05 (2-tailed) was considered statisti-
cally significant.
Results
The general characteristics of the study participants are 
shown in Table 1. The study included 207 patients with CHB 
(70  women  and  137  men  with  mean±SD  age  of  43.4±12.2 
years), 108 patients with CHC (81 women and 27 men with 
mean±SD age of 53.3±11.5 years), and 140 patients with NA-
FLD (63 women and 77 men with mean±SD age of 48.1±8.7 
years).  Bivariate  Spearman’s  rank  correlation  coefficients 
were used to assess the association between the APRI and 
hepatic  fibrosis  scores.  The  results  showed  that  the  APRI 
was significantly associated with fibrosis scores in patients 
with CHC (p = 0.2634, p = 0.0059) and NAFLD (p = 0.2273,p = 
0.0069), but not in those with CHB (p = 0.1005, p = 0.1495). 
ROC curves were used to illustrate the usefulness of the APRI 
as a predictor of the absence or presence of liver fibrosis 
(fibrosis score of 0 vs fibrosis scores of 1-4) in each group 
of patients. In patients with CHC, the APRI (optimal cut-off 
point >0.44) showed a sensitivity of 72.7% and a specificity 
of 62.4% for diagnosis of fibrosis—a fibrosis score of 1-4 (area 
under the ROC curve = 0.582, standard error = 0.069, 95% CI, 
0.519–0.697, p<0.01, Figure 1). In the NAFLD group, the APRI 
(optimal cut-off point >0.45) showed a sensitivity of 60.0% 
and a specificity of 73.3% for a fibrosis score of 1-4 (area un-
der the ROC curve = 0.627, standard error = 0.063, 95% CI, 
0.526–0.721, p<0.01, Figure 2). In patients with CHB, the APRI 
(optimal cut-off point >0.36) showed a sensitivity of 55.0% 
and a specificity of 75.4% for a fibrosis score of 1-4 (area under 
the ROC curve = 0.541, standard error = 0.047, 95% CI, 0.457–
0.622, p = NS, Figure 3). 
Discussion
Our retrospective study showed that APRI has an accept-
able accuracy for the assessment of liver fibrosis in patients 
with CHC and NAFLD, but not in those with CHB. Our results 
clearly indicate that the sensitivity of the APRI for the de-
tection of liver fibrosis depends on the etiology of chronic 
liver disease. Hepatic fibrosis, a reparative response to vari-
ous types of liver injury, has emerged as the primary deter-
minant of the outcome in advancing chronic liver disease, 
cal markers to identify hepatic fibrosis are appealing, be-
cause they are non-invasive, and repeated testing at regular 
intervals is more feasible due to lower cost (6). Several stud-
ies  have  suggested  that  the  aspartate  aminotransferases 
(AST) to platelet ratio index (APRI) may be a useful noninva-
sive marker of hepatic fibrosis in patients with chronic liver 
disease (7-12). In addition, preliminary results indicate the 
potential usefulness of the APRI for predicting significant 
fibrosis in patients with nonalcoholic fatty liver disease (NA-
FLD) (9). Importantly, simple fibrosis scores such as the APRI 
are derived from routine tests and are suitable for serial as-
sessment of patients during therapy and interventions.
Objectives
In this retrospective study, we aimed to validate in a Turk-
ish tertiary health care setting the diagnostic usefulness of 
the APRI in detection of fibrosis in those with chronic hepa-
titis C (CHC), NAFLD, and chronic hepatitis B (CHB).
Patients and Methods
All patients were recruited at the Department of Gastro-
enterology, Marmara University School of Medicine, Istan-
bul, Turkey. Written informed consent for liver biopsy had 
been  obtained  from  all  the  patients.  The  study  protocol 
was approved by the local Institutional Review Board. The 
study included 207 patients with CHB, 108 with CHC, and 
140 with NAFLD. The diagnosis of CHB or CHC infection was 
based on typical biochemical data and the detection of anti-
HCV antibodies or HBV markers. All patients with CHB were 
HBsAg-positive,  anti-HBs-negative,  and  HBV  DNA-positive. 
The diagnosis of NAFLD was based on the following crite-
ria: a) ultrasound detection of steatosis more than or equal 
to grade 1; b) absent-to-low alcohol consumption, i.e., <30 
g/day (men) and <20 g/day (women); c) exclusion of viral 
hepatitis B and C, Wilson’s disease, α1-antitrypsin deficiency, 
autoimmune hepatitis, genetic hemochromatosis, and use 
of steatogenic drugs. The entire study population was nega-
tive for other forms of viral hepatitis and human immuno-
deficiency virus (HIV) infection. Other conditions known to 
cause liver dysfunction were excluded on the basis of clini-
cal evaluation. All participants underwent liver biopsy. Ul-
trasonography-guided liver biopsies were performed under 
conscious sedation using a 16G Tru-cut needle (Quick-Core, 
Cook-Medical, Bloomington, IN, USA). Before performing the 
biopsy, we obtained written informed consent from all pa-
tients. The specimens were fixed with formalin and embed-
ded in paraffin blocks. Serial sections (sectioned at 4-mm 
intervals)  were  stained  with  hematoxylin-eosin  and  Mas-
son’s trichrome. Liver biopsy specimens were reviewed by 
one pathologist who was unaware of the patient details and 
clinical data. Serum (AST) levels were determined using an 
autoanalyzer (Roche Cobas Integra 800, Roche Diagnostics 
GmbH, Switzerland). In this study, the normal value of AST 
ranged from 5 to 40 U/L. The platelet count was performed 
on an automated hematology analyzer (Sysmex 2100, Roche 
diagnostic GmbH, Sysmex, Switzerland). The APRI was calcu-
lated as (7):
APRI= 
AST level/Upper normal limit for AST
Platelet count (10 /L)
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including cirrhosis (3-6). In light of the dramatic increase in 
the prevalence of NAFLD, noninvasive, simple, reproducible, 
and reliable biomarkers that can allow identifying patients 
with liver fibrosis are greatly needed (6). The availability of 
such biomarkers has tremendous potential to radically alter 
the diagnostic and monitoring strategies through the reduc-
tion in the need for liver biopsy (4, 15) The APRI is based on 
routine laboratory test results and is therefore readily avail-
able in the clinical practice. This index has been reported to 
predict the presence of significant fibrosis and cirrhosis in 
several investigations (7-12). However, most of the studies 
were conducted in Western Europe or in the US. Therefore, 
it is questionable whether the APRI may be used in the non-
invasive assessment of fibrosis within a broad spectrum of 
chronic liver diseases in Turkey. Wai, et al, (7) derived and val-
idated the APRI in a cohort of 270 patients with CHC. In their 
study, the area under the ROC curves of the APRI for predict-
ing  significant  fibrosis  and  cirrhosis  were  0.80–0.88  and 
0.89–0.94, respectively. Based on the high predictive values, 
the authors concluded that the APRI can obviate liver biopsy 
in approximately 50% of patients (7). Subsequently, numer-
ous researchers have attempted to validate these findings 
but the results were conflicting (16-18). The differences in 
patient populations, including the prevalence of significant 
fibrosis, and in the reference ranges for AST may in part ex-
plain these discrepancies. In a recent systematic review (12), 
it has been shown that the areas under the ROC curves of 
the APRI for predicting HCV-related significant fibrosis and 
cirrhosis were 0.76 (95% CI: 0.74–0.79) and 0.82 (95% CI: 0.79–
0.86), respectively. In keeping with previous data, the results 
of our study showed that APRI had a sensitivity of 72.7% and 
a specificity 62.4% for predicting fibrosis in patients with 
chronic HCV infection. Loaeza-del-Castillo, et al, have recent-
ly shown that the APRI tend to increase with the degree of 
fibrosis in patients with NAFLD (9). Calès and coworkers also 
observed that the use of APRI produced an area under the 
ROC curve of 0.943 in patients with NALFD (19). These results 
are in good agreement with our data and suggest that APRI 
may be a useful noninvasive marker of liver fibrosis in this 
group of patient. The prevalence of NAFLD appears to be in-
creasing worldwide, in part due to the increasing numbers 
of adult and pediatric individuals who have the metabolic 
syndrome (20, 21). Although only a minority of patients with 
NAFLD  progress  to  clinically  important  stages  of  fibrosis, 
early identification is paramount to prevent cirrhosis and 
liver cancer (20). In the present retrospective study, we did 
not find a statistically significant association between the 
APRI and fibrosis in patients with CHB. In addition, the sen-
sitivity of APRI for the detection of fibrosis in this group of 
patients was not statistically significant according to ROC 
curve analysis. Our results are in agreement with those of 
Elloumi, et al, (22) and Sebastiani, et al, (23) who provided 
evidence that APRI was not useful in predicting histology 
in chronic hepatitis B patients. Similarly, Al-Mahtab, et al, 
(24) reported that the APRI does not appear to be of use in 
predicting fibrosis in patients with CHB. It is likely that the 
lack  of  correlation  between  the  APRI  and  fibrosis  in  CHB 
is due to the platelet count. CHC (25) and NAFLD (26) have 
been associated with low platelet counts, and this might ex-
plain the usefulness of this index in these clinical entities. In 
contrast, the APRI does not clearly show a diagnostic value 
for fibrosis in CHB that would be considered adequate by 
many clinicians. However, some conflicting data exist (27). 
Different number and characteristics of subjects recruited 
and ethnical differences (Turkish subjects in this report vs 
Koreans’ (27)) might at least partially explain the differences 
among the studies. As the HBV seroprevalence rate is known 
to be 25%–60% in Turkey with the highest prevalence in the 
East and South-east (28), it would be important to devise 
noninvasive tools for assessing the degree of liver fibrosis 
in this clinical entity. In this regard, future studies should 
investigate  the  potential  usefulness  of  other  noninvasive 
tests such as FIB-4 and FORNS biochemistry indices as well 
as transient elastography (29-31). In conclusion, the results 
a Interquartile ranges were calculated as the difference between the 75th percentile and the 25th percentile.
Table 1. General characteristics of the study participants
Characteristic Chronic hepatitis B 
     (n = 207)
Chronic hepatitis C
      (n = 108)
Nonalcoholic fatty liver disease
     (n = 140)
Sex (females/males) 70/137 81/27 63/77
Age (years) 43.4 ± 12.2 53.3 ± 11.5  48.1 ± 8.7
BMI (kg/m2) 26.9 ± 3.8 27.4 ± 3.9 30.3 ± 4.3
AST (U/L)
     median (interquartile range) a
37 (25) 36 (28) 40 (22)
GGT (U/L) 
     median (interquartile range) a
42 (42) 37 (39) 46 (47)
Platelet (No/mm3) 224714 ± 62542 221851 ± 75026 249871 ± 59752
Total cholesterol (mg/dL) 183 ± 44 177 ± 38 218 ± 41
HDL cholesterol (mg/dL) 48 ± 11 49 ± 15 46 ± 9
Triglycerides (mg/dL)  
     median (interquartile range) a
101 (84) 94 (68) 166 (123)
Fibrosis score
     median (interquartile range) a
1 (2) 1 (2) 1 (2)
Fibrosis score
     mean ± SEM
1.14 ± 0.09 1.56 ± 0.12 0.89 ± 0.09
APRI
     median (interquartile range) a
0.46 (0.38) 0.49 (0.43) 0.43 (0.33)APRI in chronic liver disease 106 Yilmaz Y et al.
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Figure 3. Receiver operating characteristic (ROC) curve of APRI for prediction of fibrosis according to the Metavir system in patients with chronic hepatitis B
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Figure 1. Receiver operating characteristic (ROC) curve of APRI for prediction 
of fibrosis according to the Metavir system in ptients with chronic hepatitis C
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Figure 2. Receiver operating characteristic (ROC) curve of APRI for predic-
tion of fibrosis according to the Kleiner system in patients with NAFLD
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of our study confirm and expand previous findings showing 
that the APRI has an acceptable accuracy for the assessment 
of liver fibrosis in patients with CHC and NAFLD but not in 
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